Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New Press Release - Theratechnologies Announces Operational Update

<< Previous

Bullboard Posts

Next >>

Comment by houbahopon Oct 24, 2023 10:08am

68 Views

Post# 35698045

RE:RE:New Press Release - Theratechnologies Announces Operational Update

9 months?

How about 2 years?
They pushed it until they were on the brink of collapse.
And they were probably forced to do it by their debtholder.

Else they would have done it until receivership.

That's how weak Theratechnologies Board of Directors behave.

<< Previous

Bullboard Posts

Next >>

First Nations contributions attract investor interest